PMID- 37543027
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20230927
IS  - 1532-8198 (Electronic)
IS  - 1092-9134 (Linking)
VI  - 66
DP  - 2023 Oct
TI  - HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of 
      different scoring guidelines, clinicopathological features and prognostic impact.
PG  - 152184
LID - S1092-9134(23)00082-5 [pii]
LID - 10.1016/j.anndiagpath.2023.152184 [doi]
AB  - BACKGROUND: Clear cell carcinoma (CCC) is a rare high-grade adenocarcinoma 
      associated with poor response to platinum-based chemotherapy agents in the female 
      genital tract. Human epidermal growth factor receptor 2 (HER2) overexpression is 
      routinely used as a biomarker for targeted therapy in breast and gastric 
      carcinomas, but its role in CCC remains unclear. METHODS: In this study, HER2 
      overexpression was evaluated by immunohistochemistry (IHC) using College of 
      American Pathologists (CAP) HER2 scoring guidelines for breast and endometrial 
      serous carcinoma (ESC) on tissue microarray blocks. In equivocal and positive 
      cases, fluorescence in situ hybridization (FISH) was performed. IHC score 3, and 
      all amplified cases on FISH test were considered positive. RESULTS: Thirty-six 
      cases of ovarian (OCCC), 36 endometrial (ECCC), and 2 cervical CCC were included. 
      According to ESC and breast scoring guidelines, 20 % and 15.1 % of ECCC and 
      14.7 % and 6 % of OCCC were HER2 positive, respectively. Both cases of cervical 
      CCC were negative. Scoring based on breast carcinoma guideline showed higher 
      concordance (100 %) with gene amplification results, in comparison with ESC 
      guideline (82.7 %). On multivariate survival analysis, HER2 positive ECCC and 
      OCCC (based on ESC scoring methods) had significantly lower overall and 
      disease-free survivals (OS, DFS) (P < 0.05). CONCLUSION: HER2 immunoscoring based 
      on ESC guideline can yield a higher sensitivity with relevant clinical and 
      prognostic features in OCCC and ECCC. HER2 can be considered a potential 
      biomarker for targeted therapy and future clinical trials.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Edjtemaei, Ramtin
AU  - Edjtemaei R
AD  - Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Nili, Fatemeh
AU  - Nili F
AD  - Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of 
      Medical Sciences, Tehran, Iran. Electronic address: f-nili@sina.tums.ac.ir.
FAU - Jahanzad, Issa
AU  - Jahanzad I
AD  - Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Ameli, Fereshteh
AU  - Ameli F
AD  - Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Ghasemi, Dorsa
AU  - Ghasemi D
AD  - Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230726
PL  - United States
TA  - Ann Diagn Pathol
JT  - Annals of diagnostic pathology
JID - 9800503
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Female
MH  - Humans
MH  - Biomarkers, Tumor/analysis
MH  - *Breast Neoplasms/pathology
MH  - *Carcinoma
MH  - *Cystadenocarcinoma, Serous/diagnosis
MH  - *Endometrial Neoplasms/metabolism
MH  - Endometrium/pathology
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Prognosis
MH  - *Receptor, ErbB-2/metabolism
OTO - NOTNLM
OT  - Clear cell carcinoma
OT  - Clinicopathologic features
OT  - Endometrium
OT  - HER2
OT  - Ovary
OT  - Prognosis
OT  - Scoring
COIS- Declaration of competing interest None.
EDAT- 2023/08/06 05:42
MHDA- 2023/09/22 06:42
CRDT- 2023/08/05 18:11
PHST- 2023/06/30 00:00 [received]
PHST- 2023/07/25 00:00 [revised]
PHST- 2023/07/26 00:00 [accepted]
PHST- 2023/09/22 06:42 [medline]
PHST- 2023/08/06 05:42 [pubmed]
PHST- 2023/08/05 18:11 [entrez]
AID - S1092-9134(23)00082-5 [pii]
AID - 10.1016/j.anndiagpath.2023.152184 [doi]
PST - ppublish
SO  - Ann Diagn Pathol. 2023 Oct;66:152184. doi: 10.1016/j.anndiagpath.2023.152184. 
      Epub 2023 Jul 26.